Article info
PDFCorrespondence response
Response to: ‘Correspondence on ‘Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial’’ by Satis et al
- Correspondence to Dr Seza Ozen, Pediatric Rheumatology, Hacettepe University, Ankara 06800, Turkey; sezaozen{at}gmail.com
Citation
Response to: ‘Correspondence on ‘Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial’’ by Satis et al
Publication history
- Received August 28, 2020
- Accepted August 30, 2020
- First published September 28, 2020.
Online issue publication
November 10, 2022
Article Versions
- Previous version (28 September 2020).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.